A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Trial Profile

A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Jan 2012 Results published in the Journal of Hepatology.
    • 12 Oct 2009 Primary endpoint 'Objective clinical response rate' has not been met in the primary treatment phase.
    • 12 Oct 2009 Results from the primary treatment phase have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top